FDA Clinical Hold Types: Full Hold, Partial Hold, and Resolution
An FDA clinical hold is an order issued under 21 CFR 312.42 that suspends or prevents clinical trials under an Investigational New Drug (IND) application from proceeding. A full clinical hold stops all clinical work under the IND, while a partial clinical hold restricts specific aspects (e.g., a particular study, dose level, or patient population) while allowing other activities to continue. FDA must notify the sponsor promptly (typically by telephone) and provide written notification within 30 days stating the reasons for the hold. The sponsor must address the cited deficiencies before FDA lifts the hold. For response strategies, see our IND clinical hold response guide.
Key Takeaways
Key Takeaways
- A full clinical hold under 21 CFR 312.42 stops all clinical work under the IND; a partial hold restricts specific studies, doses, or populations
- FDA must notify the sponsor by telephone and provide written notification within 30 days stating the reasons and required corrective actions
- Sponsors can request a Type A meeting (scheduled within 30 days) to discuss clinical hold resolution
- FDA must respond to the sponsor's complete clinical hold response within 30 days
- Safety reporting obligations under 21 CFR 312.32 continue during a clinical hold for subjects already treated
- Clinical holds are one of the most serious regulatory actions FDA can take during drug development. They halt human testing of an investigational product, directly affecting clinical trial timelines, patient enrollment, and development program viability.
- Understanding the different types of clinical holds, the specific grounds on which FDA can impose them, the response process, and the connection to IND safety reporting is essential for sponsors, clinical teams, and regulatory professionals managing investigational programs.
- In this guide, you will learn:
- The regulatory basis for clinical holds under 21 CFR 312.42
- The difference between full clinical holds and partial clinical holds
- Specific grounds for clinical hold by study phase
- The 30-day notification requirement and what FDA must communicate
- Sponsor response requirements and the resolution process
- The connection between IND safety reporting and clinical hold triggers
- ---
Regulatory Basis: 21 CFR 312.42
Authority and Scope
FDA's authority to impose clinical holds on investigational drugs is codified in 21 CFR 312.42. This regulation applies to all IND applications, including commercial INDs (sponsor is the drug company) and investigator INDs (sponsor is the investigator).
Under 21 CFR 312.42(a), FDA may order a clinical hold of a "proposed or ongoing" clinical investigation. The regulation specifies:
- Proposed studies: FDA can prevent a study from starting (e.g., placing a hold on an IND before the initial study begins or on a protocol amendment proposing a new study)
- Ongoing studies: FDA can suspend a study that is already enrolling or treating patients
When the 30-Day IND Review Period Applies
For a new IND application, the sponsor must wait 30 calendar days after FDA receives the IND before initiating clinical trials (21 CFR 312.40(b)). During this 30-day period, FDA reviews the IND and can impose a clinical hold if the information submitted does not support safe initiation of the proposed study.
If FDA does not impose a clinical hold within 30 days, the IND is considered "active" and the sponsor may proceed with the proposed clinical trial. However, FDA retains the authority to impose a clinical hold at any time after the 30-day period if safety concerns arise.
Full Clinical Hold
Definition
A full clinical hold orders the complete suspension of all clinical work under the IND. No new subjects may be enrolled, and ongoing subjects may not continue to receive the investigational product except as necessary to protect their safety (e.g., gradual dose tapering rather than abrupt discontinuation).
Under 21 CFR 312.42, a full clinical hold is an FDA order that prohibits the sponsor from conducting any clinical investigation under the specified IND application until the hold is lifted.
Impact of a Full Clinical Hold
| Aspect | Impact |
|---|---|
| New enrollment | Prohibited |
| Ongoing treatment of enrolled subjects | Stopped, except where necessary for subject safety |
| Safety monitoring | Must continue for all subjects who received the investigational product |
| IND amendments | May still be submitted (e.g., to address the hold concerns) |
| Other INDs by same sponsor | Not affected unless they share the same safety concern |
| Clinical trial sites | Must be notified immediately; IRBs must be informed |
Grounds for a Full Clinical Hold
The grounds for imposing a clinical hold differ by study phase. Under 21 CFR 312.42(b), FDA may impose a clinical hold for the following reasons:
Phase 1 Studies (21 CFR 312.42(b)(1))
| Ground | Description |
|---|---|
| Unreasonable risk | Human subjects would be exposed to an unreasonable and significant risk of illness or injury |
| Unqualified investigators | Clinical investigators are not qualified by training and experience to conduct the investigation |
| Misleading investigator brochure | The investigator brochure is misleading, erroneous, or materially incomplete |
| Insufficient IND content | The IND does not contain sufficient information required under 21 CFR 312.23 to assess risks |
Phase 2 and Phase 3 Studies (21 CFR 312.42(b)(2))
All Phase 1 grounds apply, plus:
| Ground | Description |
|---|---|
| Insufficient study design | The clinical investigation protocol design is clearly deficient in meeting its stated objectives |
For Phase 2 and Phase 3 studies, FDA has all the same grounds for a clinical hold as Phase 1 plus an additional ground: deficient protocol design. This means the regulatory basis for holds is actually broader in later phases. However, in practice, more clinical experience with the product means FDA evaluates safety signals against a larger context of accumulated data. New safety data (from the IND or external sources) can always trigger a hold regardless of development phase.
Partial Clinical Hold
Definition
A partial clinical hold restricts specific aspects of an investigational program while allowing other activities to continue. This is a more targeted action that addresses specific safety concerns without shutting down the entire IND.
Under 21 CFR 312.42, a partial clinical hold is an FDA order that restricts certain clinical investigations or aspects of investigations under an IND while permitting other studies or study activities to proceed.
What a Partial Hold Can Restrict
| Restriction Type | Example |
|---|---|
| Specific study | Hold on a Phase 3 study while Phase 1 PK studies continue |
| Dose level | Hold on the highest dose cohort while lower doses continue |
| Patient population | Hold on studies in pediatric patients while adult studies continue |
| Duration of treatment | Hold on long-term extension studies while acute treatment studies continue |
| Route of administration | Hold on IV studies while oral formulation studies continue |
| New enrollment only | Prohibition on enrolling new subjects while allowing ongoing subjects to complete treatment |
Full Hold vs Partial Hold Comparison
| Attribute | Full Clinical Hold | Partial Clinical Hold |
|---|---|---|
| Scope | All clinical work under the IND | Specified studies, doses, populations, or activities |
| New enrollment | Prohibited across entire IND | Prohibited only in specified scope |
| Ongoing treatment | Stopped (except for subject safety) | Continues outside the restricted scope |
| Other studies under same IND | All suspended | Non-restricted studies continue |
| Regulatory basis | 21 CFR 312.42(a) | 21 CFR 312.42(a) |
| Resolution process | Same as full hold | Same as full hold |
| Frequency | More common for serious, broad safety concerns | More common for targeted safety or design issues |
FDA Notification Requirements
The 30-Day Notification Rule
Under 21 CFR 312.42(d), when FDA imposes a clinical hold, the agency must:
- Notify the sponsor by telephone or other rapid communication means
- Provide written notification within 30 days of ordering the hold, stating:
- The reasons for the hold
- The specific deficiencies that must be addressed
- The conditions under which the hold may be lifted
What the Written Notification Must Contain
| Element | Requirement |
|---|---|
| Identification of the IND | IND number, drug name, sponsor |
| Type of hold | Full or partial; specific scope of partial hold |
| Grounds for the hold | Specific regulatory basis under 21 CFR 312.42(b) |
| Deficiencies cited | Detailed description of the safety concerns or protocol deficiencies |
| Required actions | What the sponsor must do to address the deficiencies |
| Contact information | FDA review division contact for questions and follow-up |
Timing Nuances
| Scenario | FDA Action Timeline |
|---|---|
| Hold during 30-day IND review | FDA notifies sponsor before the 30-day period expires; study cannot begin |
| Hold on an active IND | FDA notifies sponsor immediately; sponsor must stop affected activities upon notification |
| Written notice after telephone notification | Must be provided within 30 days of the hold order |
The telephone notification is the operative action. Once FDA communicates the hold by phone, the sponsor must comply immediately, even if the written notification has not yet arrived. Do not wait for the written notice to take action. Begin preparing your response and notifying clinical sites, IRBs, and investigators immediately upon receiving the phone call.
Sponsor Response Requirements
What the Sponsor Must Do
Under 21 CFR 312.42(e), the sponsor may respond to the clinical hold by:
- Addressing the deficiencies identified in FDA's hold notification
- Submitting a complete response to the IND containing the information needed to resolve the concerns
- Requesting a meeting (Type A meeting) to discuss the hold and the proposed resolution
Response Format
| Element | Description |
|---|---|
| Cover letter | Reference the clinical hold notification, IND number, and date of hold |
| Complete response to each deficiency | Address every deficiency cited by FDA, point by point |
| Supporting data | Include new or existing data that addresses the safety or design concerns |
| Revised protocol (if applicable) | If protocol design was cited, submit amended protocol |
| Updated investigator brochure (if applicable) | If new safety data necessitate updates |
| eCTD format | Submit as an IND amendment in proper eCTD format |
Response Timeline
There is no regulatory deadline for the sponsor to respond to a clinical hold. However:
- The clinical hold remains in effect until FDA notifies the sponsor that the hold is lifted
- Prolonged holds have significant consequences for trial timelines, patient enrollment, and development strategy
- Prompt response is in the sponsor's interest
While there is no formal deadline, aim to submit your clinical hold response within 30-60 days of receiving the hold notification. Faster responses are better, but accuracy and completeness are more important than speed. A hasty, incomplete response that fails to address FDA's concerns will not result in hold removal and may complicate the situation.
Clinical Hold Resolution Process
How a Clinical Hold Is Lifted
Under 21 CFR 312.42(e), the clinical hold resolution process is:
| Step | Action | Timeline |
|---|---|---|
| 1 | Sponsor submits complete response addressing all cited deficiencies | No fixed deadline; sponsor-dependent |
| 2 | FDA reviews the sponsor's response | Within 30 days of receiving a complete response |
| 3 | FDA determines whether deficiencies have been adequately addressed | Part of the 30-day review |
| 4 | FDA notifies sponsor of decision | Within 30 days of receiving the complete response |
The 30-Day Review Commitment
Under 21 CFR 312.42(e), FDA is required to respond to the sponsor's clinical hold submission within 30 days:
- If FDA determines the deficiencies have been addressed: FDA lifts the hold and notifies the sponsor
- If FDA determines the response is inadequate: FDA maintains the hold and communicates the remaining concerns
- If the response raises new questions: FDA may request additional information
Possible Outcomes After Sponsor Response
| Outcome | Description | Sponsor Action |
|---|---|---|
| Hold lifted | FDA is satisfied; clinical work may resume | Notify sites, IRBs, investigators; resume enrollment |
| Hold maintained, additional information requested | Response was partially adequate; specific additional data needed | Address remaining concerns and resubmit |
| Hold maintained, response inadequate | Fundamental concerns unresolved | Reassess development strategy; consider Type A meeting |
| Partial lift | Full hold converted to partial hold | Resume permitted activities; address remaining restricted scope |
Requesting a Type A Meeting for Clinical Hold
A clinical hold qualifies for a Type A meeting, which FDA must schedule within 30 calendar days of the sponsor's meeting request. Type A meetings are reserved for the most urgent matters, and clinical holds are explicitly identified as qualifying situations.
When to Request a Type A Meeting
| Scenario | Recommendation |
|---|---|
| FDA's concerns are clear and actionable | Respond directly; meeting may not be necessary |
| Deficiencies are ambiguous or broad | Request Type A meeting to clarify what FDA expects |
| Sponsor disagrees with FDA's assessment | Request Type A meeting to present alternative interpretation |
| Multiple resolution pathways exist | Request Type A meeting to discuss preferred approach |
| New data change the safety picture | Request Type A meeting to present updated safety analysis |
Meeting Preparation
| Element | Content |
|---|---|
| Meeting request | Reference IND number, clinical hold notification, and state purpose of meeting |
| Briefing document | Provide sponsor's response to each deficiency with supporting data |
| Specific questions | Frame questions to elicit clear, actionable FDA guidance |
| Proposed resolution plan | Present the sponsor's plan for addressing each deficiency |
| Timeline | Propose a timeline for submitting the complete response after the meeting |
IND Safety Reporting Connection
How Safety Reports Trigger Clinical Holds
IND safety reporting requirements under 21 CFR 312.32 can directly lead to clinical hold imposition. When FDA receives safety reports that indicate:
| Safety Report Type | Clinical Hold Connection |
|---|---|
| Individual Case Safety Reports (ICSRs) | A pattern of serious adverse events may trigger FDA to evaluate whether a clinical hold is warranted |
| IND Safety Reports (21 CFR 312.32) | Reports of suspected unexpected serious adverse reactions (SUSARs) that suggest an unreasonable risk |
| Annual Reports (21 CFR 312.33) | Cumulative safety data indicating emerging safety signals |
| Data Safety Monitoring Board (DSMB) reports | DSMB recommendations to pause or stop a study may prompt FDA action |
| Published literature | External safety data from similar products or mechanisms may trigger FDA concern |
Sponsor Safety Reporting Obligations During a Hold
While a clinical hold is in effect, the sponsor must continue to:
| Obligation | Regulatory Basis |
|---|---|
| Report safety information for subjects already treated | 21 CFR 312.32 |
| Submit annual IND reports | 21 CFR 312.33 |
| Monitor subjects for adverse events | 21 CFR 312.32(d) |
| Update the investigator brochure with new safety data | 21 CFR 312.55 |
| Notify IRBs and investigators of the clinical hold | 21 CFR 312.56 |
Safety data generated during a clinical hold (from ongoing follow-up of previously treated subjects) may be critical to resolving the hold. If follow-up data show that the safety signal was transient, dose-dependent, or manageable with monitoring, this information strengthens the sponsor's case for hold removal. Ensure robust safety follow-up continues throughout the hold period.
Clinical Hold Statistics and Context
Frequency
FDA does not routinely publish comprehensive clinical hold statistics, but available data indicate:
- Clinical holds are relatively uncommon relative to the total number of active INDs
- Phase 1 INDs for first-in-human studies have a higher hold rate than later-phase INDs
- INDs for products with novel mechanisms of action, gene therapies, and cell-based therapies have received increased FDA scrutiny and higher hold rates in recent years
- CMC-related holds (e.g., manufacturing deficiencies affecting product quality) have become more common
Common Clinical Hold Reasons by Therapeutic Area
| Therapeutic Area | Common Hold Reasons |
|---|---|
| Oncology | Dose-limiting toxicities, inadequate dose-escalation design, insufficient nonclinical safety data (may also trigger FDA Form 483 findings at manufacturing sites) |
| Gene therapy | Insertional mutagenesis concerns, vector shedding, insufficient nonclinical data on biodistribution |
| Cell therapy | Manufacturing consistency, tumorigenicity risk, insufficient characterization |
| CNS | Suicidality signals, neurotoxicity concerns, abuse potential |
| Infectious disease | Resistance emergence, hepatotoxicity, bone marrow suppression |
Key Regulatory References
| Document | Relevance |
|---|---|
| 21 CFR 312.42 | Clinical hold procedures: imposition, grounds, notification, and resolution |
| 21 CFR 312.40 | General requirements for IND and the 30-day review period |
| 21 CFR 312.32 | IND safety reporting requirements |
| 21 CFR 312.33 | IND annual report requirements |
| 21 CFR 312.23 | IND content and format requirements |
| 21 CFR 312.55 | Sponsor obligation to update investigator brochure |
| 21 CFR 312.56 | Sponsor obligation to notify investigators and IRBs |
| FDA Guidance: "Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products" (Rev. 2017) | Type A meeting procedures for clinical hold discussions |
| FDA Guidance: "Safety Reporting Requirements for INDs and BA/BE Studies" (Rev. 2012) | Safety reporting that may trigger clinical holds |
How long does a clinical hold last?
There is no predetermined duration. A clinical hold remains in effect until FDA is satisfied that the deficiencies have been adequately addressed and notifies the sponsor that the hold is lifted. Some holds are resolved within weeks; others persist for months or longer.
Can subjects continue treatment during a full clinical hold?
Generally no. However, if abrupt discontinuation of the investigational product would pose a safety risk to the subject (e.g., risk of withdrawal syndrome, disease rebound), the sponsor may continue treatment under a controlled tapering protocol. This must be discussed with FDA.
Does a clinical hold affect other INDs for the same drug?
Not automatically. A clinical hold is issued against a specific IND. However, if the safety concern applies broadly to the drug substance (e.g., a class-wide toxicity signal), FDA may separately hold other INDs for the same or related products.
Can FDA impose a clinical hold without notifying the sponsor first?
FDA must notify the sponsor of the hold, but the hold takes effect upon notification. There is no pre-notification or "warning" period. The first communication is the hold order itself.
What is the difference between a clinical hold and a DSMB recommendation to stop a trial?
A DSMB recommendation is advisory to the sponsor. A clinical hold is a regulatory order from FDA. The DSMB may recommend stopping a trial based on interim data, but only FDA can impose a clinical hold. However, DSMB recommendations often influence FDA's decision to impose a hold.
Can the sponsor voluntarily pause a trial instead of receiving a clinical hold?
Yes. Sponsors can voluntarily suspend enrollment or treatment at any time. A voluntary suspension is not a clinical hold and does not carry the same regulatory implications. However, if FDA believes the sponsor's voluntary action is insufficient, it can still impose a formal clinical hold.